Diffuse hyperpigmented lichenoid drug eruption secondary to Enzalutamide

Abstract

Enzalutamide is a potent second-generation androgen receptor (AR) antagonist used to treat metastatic castration resistant prostate carcinoma (mCPRC) and metastatic hormone sensitive prostate carcinoma (mHSPC). Side effects of enzalutamide include headaches, fatigue, hot flashes, xerosis and pruritus. Enzalutamide, however, has the fewest reported cutaneous adverse outcomes of any AR inhibitor. We report, to our knowledge, the first clinical presentation of a lichenoid drug eruption secondary to enzalutamide treatment in a 55-year-old-male with mCPRC.

Keywords

• Enzalutamide
• Drug eruption
• Prostate cancer
• Adverse event